Stockwinners Market Radar for November 05, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

DIS...

Hot Stocks

20:02 EDT On The Fly: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. T-Mobile (TMUS) and Sprint (S) jointly announced that they have ceased talks to merge as the companies were unable to find mutually agreeable terms. Meanwhile, Sprint and Altice USA (ATUS) announced a new multi-year strategic agreement. Under the terms of the agreement Altice USA will utilize Sprint's network to provide mobile voice and data services to its customers throughout the nation, and Sprint will leverage the Altice USA broadband platform to accelerate the densification of its network. SoftBank (SFTBF) also announced that it intends to increase its stake in Sprint through open market transactions or otherwise, subject to market conditions and other factors. 2. A gunman killed at least 26 worshipers and wounded 20 others at a white-steepled church in southeast Texas on Sunday, according to Reuters, citing authorities. The gunman, described as a white man in his 20s, was fired on by a local resident, fled in his vehicle and was later found dead in neighboring Guadalupe County, the publication noted, adding that it was not immediately clear if the suspect killed himself or was hit by gunfire by the resident. 3. Artificial intelligence has been perceived to be a threat to Intel's (INTC) decades-long dominance in computer chips, but its shares are up 30% this year, maybe due to third quarter earnings or maybe due to its plans to release a new line of A.I. chips developed in collaboration with Facebook (FB), and as the company's purchase of Mobileye makes it an early leader in autonomous driving, Jack Hough wrote in this week's edition of Barron's, adding that he still sees more upside ahead. 4. Disney (DIS) and Marvel Studios' "Thor: Ragnarok" opened to $121M from 4,080 theaters in North America. Overseas, the threequel grossed $151.4M in its second weekend for a foreign tally of $306M. The pic with Chris Hemsworth returning in the titular role earned 93% from Rotten Tomatoes. 5. IBM (IBM), Alphabet (GOOG; GOOGL), AMD (AMD), Impinj (PI), Everspin Technologies (MRAM), Matel (MAT), Facebook, Cummins (CMI), United Technologies (UTX), Honeywell (HON), Ingersoll-Rand (IR), and Illinois Tool Works (ITW) saw positive mentions in Barron's, while Under Armour (UAA) was mentioned cautiously.
TWX...

Hot Stocks

19:36 EDT Box Office Battle: 'Thor: Ragnarok' wins weekend with $121M - Disney (DIS) and Marvel Studios' "Thor: Ragnarok" opened to $121M from 4,080 theaters in North America. Overseas, the threequel grossed $151.4M in its second weekend for a foreign tally of $306M. The pic with Chris Hemsworth returning in the titular role earned 93% from Rotten Tomatoes. BOX OFFICE RUNNERS-UP: "A Bad Moms Christmas" came in second, ending the weekend with $17M and a five-day debut of $21.6M, hampered by generally bad reviews and a B CinemaScore. Behind it was Lionsgate's (LGF.A) "Jigsaw," earning an estimated $6.7M from 2,941 theaters. Lionsgate also took number fourth this weekend, with its "Boo 2! A Madea Halloween" grossing about $4.7M from about 2,200 theaters. Rounding out the top five, Warner Bros. (TWX) "Geostorm" grossed $3M for a domestic total of $28.8M. Other publicly traded companies in filmmaking include Sony (SNE), Comcast (CMCSA; CMCSK), 21st Century Fox (FOXA), and Walt Disney (DIS).
RHT...

Hot Stocks

19:16 EDT Red Hat announces OpenStack Platform 12 - Red Hat (RHT) announced Red Hat OpenStack Platform 12, the latest version of Red Hat's massively scalable and agile cloud Infrastructure-as-a-Service. Based on the OpenStack "Pike" release, Red Hat OpenStack Platform 12 introduces containerized services, improving flexibility while decreasing complexity for faster application development. Red Hat OpenStack Platform 12 delivers many new enhancements, including upgraded DCI and improved security to help maintain data compliance and manage risk. Hundreds of customers rely on Red Hat OpenStack Platform to power their hybrid and private clouds for a variety of mission-critical deployments. Red Hat OpenStack Platform is backed by a robust ecosystem of partners, including Cisco (CSCO), Dell EMC (DELL), Intel (INTC), Lenovo (LNVGY), Rackspace (RAX), and NetApp (NTAP) for enterprise businesses. Red Hat OpenStack Platform 12 is designed for private or public cloud infrastructure, built on the enterprise-grade backbone of Red Hat Enterprise Linux. Red Hat OpenStack Platform 12 is a tested, certified, and fully-supported version of OpenStack that provides the agility to scale and more quickly meet customer demand without compromising availability, performance, or IT security requirements. Red Hat OpenStack Platform also includes Red Hat CloudForms, Red Hat's multi-cloud management platform, to provide operational visibility and policy-based management across the Red Hat OpenStack Platform infrastructure and workloads. Additionally, Red Hat OpenStack Platform 12 maintains tight integration with Red Hat Ceph Storage, a highly-scalable block, object, and file storage solution, designed for scale-out clouds.
JNPR RHT

Hot Stocks

17:37 EDT Juniper democratizes Telcon Cloud with Contrail Cloud Enhancements - Juniper Networks (JNPR) announced enhancements to Contrail Cloud to help service providers mitigate the challenges in building and operating distributed and scalable clouds. These updates, including integration of OpenStack Platform and Ceph Storage from leading open source solutions provider Red Hat (RHT), built-in AppFormix automation and visibility, pre-validated virtual network functions and new end-to-end support services, give carriers a far simpler path to delivering business, IoT and mobile services in the cloud. Contrail Cloud makes deploying the telco cloud far easier through simplifying the underlying Linux distribution with Red Hat, seamlessly gleaning network insight with AppFormix, clearing the traditionally difficult task of validating VNFs by pre-qualifying, and adding end-to-end support services to smooth implementation. Companies can use this integrated solution to easily navigate the complexities of cloud deployments and operations with improved performance and scale, and service SLAs.
SFTBF...

Hot Stocks

17:34 EDT SoftBank announces intention to increase stake in Sprint - SoftBank (SFTBF) announced that it intends to increase its stake in Sprint (S) through open market transactions or otherwise, subject to market conditions and other factors. SBG does not intend to increase its ownership of Sprint outstanding common stock to 85% or more as a result of these purchases. Sprint announced yesterday that discussions regarding a potential merger with T-Mobile (TMUS) have ended without an agreement being reached.
S ATUS

Hot Stocks

17:31 EDT Sprint, Altice USA announce strategic agreement - Sprint (S) and Altice USA (ATUS) announced a new multi-year strategic agreement. Under the terms of the agreement Altice USA will utilize Sprint's network to provide mobile voice and data services to its customers throughout the nation, and Sprint will leverage the Altice USA broadband platform to accelerate the densification of its network. Sprint will provide Altice USA with access to its full MVNO model, allowing Altice USA to connect its network to the Sprint Nationwide network and have control over the Altice USA mobile features, functionality, and customer experience. In exchange, Altice USA will leverage its network to support Sprint's network densification efforts and establish a differentiated network operating model going forward.
LUV

Hot Stocks

17:19 EDT Southwest launches service to Turks and Caicos Islands - Southwest Airlines began operating new international service daily from Ft. Lauderdale-Hollywood International Airport to Providenciales International Airport in the Turks and Caicos Islands, the carrier's 11th country served. In addition, Southwest initiated new service between its South Florida gateway at FLL and both San Jose, Costa Rica, and Punta Cana, Dominican Republic, giving Customers nonstop access from Fort Lauderdale to 10 destinations in Latin America and the Caribbean.
LLY...

Hot Stocks

17:17 EDT Patients treated with Eli Lilly/Incyte Baricitinib reported greater improvements - Eli Lilly (LLY) and Incyte (INCY) announced that patients with moderate-to-severe rheumatoid arthritis treated with baricitinib reported greater improvements in pain control when compared to AbbVie's (ABBV) Humira or placebo. A new post-hoc analysis of the Phase 3 RA-BEAM study disclosing outcomes of patient-reported levels of pain control will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting in San Diego, Calif. RA-BEAM was a 52-week trial of 1,305 patients who had active, moderate-to-severe RA, despite ongoing treatment with methotrexate. Patients were randomized to placebo once daily, baricitinib 4 mg once daily or adalimumab 40 mg biweekly. All patients received background methotrexate. This post-hoc analysis reviewed outcomes of patient-reported levels of pain control during the first 24 weeks of the trial as measured by a 0-100 mm visual analog scale during each study visit. Analyses were not adjusted for multiplicity, were exploratory in nature and further research should be conducted to confirm these results. Analysis of reduction in pain included an assessment of the time required to achieve greater than or equal to 30%, greater than or equal to 50% and greater than or equal to 70% pain improvement. The observed safety profile in RA-BEAM was consistent with previous trials evaluating baricitinib. The percentage of patients stopping therapy due to adverse events through Week 24 were 3% in placebo, 5% in baricitinib and 2% in the adalimumab group. Serious adverse event rates through 24 weeks were similar with placebo and baricitinib and lower with adalimumab. No additional safety signals were observed during the post-hoc analysis. Lilly plans to resubmit the New Drug Application with the U.S. Food and Drug Administration for baricitinib as a treatment for adult patients with RA before the end of January 2018. Baricitinib is approved for the treatment of adult patients with RA in several geographies, including the European Union and Japan.
GLPG

Hot Stocks

17:11 EDT Galapagos announces consistent safety findings in DARWIN 3 study - Galapagos NV announced additional long-term follow-up data for the investigational agent filgotinib in patients with moderate to severely active rheumatoid arthritis from the DARWIN 3 study. In this 84-week analysis of 560 patients representing 1,708 patient years of exposure, adverse events and treatment emergent lab abnormalities were consistent with prior safety results and filgotinib was shown to have durable activity; data are summarized in the abstract. These data and other filgotinib studies, as well as the Phase 1 First-in-Human results with Galapagos' investigational agent GLPG1972 in osteoarthritis, will be presented during the American College of Rheumatology Annual Meeting 2017 in San Diego, CA.
ANTH

Hot Stocks

17:05 EDT Anthera announces presentation of Blisibimod Data - Anthera Pharmaceuticals will present additional findings from the CHABLIS-SC1, Phase 3 clinical study of blisibimod, a novel treatment that targets B-cell activating factor, at the American College of Rheumatology Annual Meeting in San Diego from November 3-8.
XNCR

Hot Stocks

10:06 EDT Xencor presents final results from Phase 2 study of XmAb5871 - Xencor has announced the final results from a Phase 2 study of XmAb5871 in patients with active IgG4-RD. Data show that 12 of 15 patients completed the study, and all 12 achieved the primary endpoint of at least a two-point reduction in the IgG4-RD Responder Index on Day 169. None of the 12 required corticosteroids after month two. Eight patients achieved remission and the other four achieved IgG4-RD RI scores of less than or equal to4 at Day 169. Fourteen of 15 patients achieved a decrease of greater than or equal to 5 in the IgG4-RD RI. One patient had been on baseline CS for two years and was able to discontinue CS within two months. Four others received CS at the start of the trial and tapered off within two months. XmAb5871 was well tolerated. Three patients had minor, transient GI side-effects during the first infusion; all completed the study. Two serious adverse events unrelated to XmAb5871 were observed in one patient, pneumonia and recurrence of pneumonia due to non-compliance. Three patients discontinued the study, as disclosed previously. One discontinued patient was atypical with laryngeal involvement only who did not respond to XmAb5871 or to subsequent rituximab. A second patient responded, but flared at 12 weeks and did not respond to subsequent rituximab therapy. The third patient responded but developed infusion-related symptoms including transient rash and arthralgias following the fifth infusion. Plasmablasts were reduced 70%-80% from baseline and B cells were reduced 40-55% from baseline, with decreases occurring within the first two weeks.
AVXL

Hot Stocks

10:01 EDT Anavex presents new data of Alzheimer's treatment ANAVEX2-73 - Anavex presented new clinical pharmacokinetic and pharmacodynamic data for ANAVEX2-73 in a late-breaking oral presentation at the 2017 Clinical Trials on Alzheimer's Disease Meeting. Data presented include new results from the Phase 1 study, the Phase 2a study, and data from the first year of the Phase 2a long-term extension study. At 109 weeks and halfway into the long-term extension Phase 2a study ANAVEX2-73-003, data from the cohort of patients with the highest ANAVEX2-73 concentrations point toward the continued ability of the medication to stop the decline in the exploratory secondary endpoints cognition and function. At 57 weeks, this cohort had demonstrated improvement of the measures MMSE and ADCS-ADL compared to baseline. For the primary endpoint, ANAVEX2-73 demonstrated continued favorable safety and tolerability through 109 weeks. Additionally, clinical data from 54 subjects from the Phase 1 and the Phase 2a trials were analyzed including using formal concept analysis, non-linear mixed effect modeling and non-compartmental analysis methods. This data provide support to proceed with the clinical development of ANAVEX2-73 for Alzheimer's disease in a focused Phase 2/3 study using the precision medicine paradigm, including DNA whole exome, RNA expression and gut microbiome characterization. Further clinical studies in other indications, such as Rett syndrome and Parkinson's disease are under development utilizing the translational potential of precision medicine approach of ANAVEX2-73. ANAVEX2-73 is a novel, orally available sigma-1 receptor agonist. Sigma-1 receptor, an emerging therapeutic target in Alzheimer's disease and other central nervous system disorders, has been shown to reduce cellular stress and regulate neuroplasticity and cellular homeostasis. The Company previously reported that the Phase 2a trial successfully achieved both primary and secondary endpoints.
S...

Hot Stocks

09:48 EDT Spring, T-Mobile cease discussions to merge - T-Mobile (TMUS) and Sprint (S) jointly announced that they have ceased talks to merge as the companies were unable to find mutually agreeable terms. The latter's President and Softbank (SFTBF) Board member Marcelo Claure said: "While we couldn't reach an agreement to combine our companies, we certainly recognize the benefits of scale through a potential combination. However, we have agreed that it is best to move forward on our own. We know we have significant assets, including our rich spectrum holdings, and are accelerating significant investments in our network to ensure our continued growth. As convergence in the connectivity marketplace continues, we believe significant opportunities exist to establish strong partnerships across multiple industries. We are determined to continue our efforts to change the wireless industry and compete fiercely. We look forward to continuing to take the fight to the duopoly and newly emerging competitors." In a statement, John Legere, President and CEO of T-Mobile also said: "The prospect of combining with Sprint has been compelling for a variety of reasons, including the potential to create significant benefits for consumers and value for shareholders. However, we have been clear all along that a deal with anyone will have to result in superior long-term value for T-Mobile's shareholders compared to our outstanding stand-alone performance and track record." "Going forward, T-Mobile will continue disrupting this industry and bringing our proven Un-carrier strategy to more customers and new categories - ultimately redefining the mobile Internet as we know it. We've been out-growing this industry for the last 15 quarters, delivering outstanding value for shareholders, and driving significant change across wireless. We won't stop now," Legere added.
S TMUS

Hot Stocks

09:38 EDT T-Mobile, Sprint end merger talks - T-Mobile (TMUS) has announced that it has ceased talks to merge with Sprint (S), as the companies were unable to find mutually agreeable terms. "The prospect of combining with Sprint has been compelling for a variety of reasons, including the potential to create significant benefits for consumers and value for shareholders. However, we have been clear all along that a deal with anyone will have to result in superior long-term value for T-Mobile's shareholders compared to our outstanding stand-alone performance and track record," said John Legere, President and CEO of T-Mobile. "Going forward, T-Mobile will continue disrupting this industry and bringing our proven Un-carrier strategy to more customers and new categories - ultimately redefining the mobile Internet as we know it. We've been out-growing this industry for the last 15 quarters, delivering outstanding value for shareholders, and driving significant change across wireless. We won't stop now."